Cowen Raises Price Target on Seattle Genetics (SGEN) Following 2Q15
Get Alerts SGEN Hot Sheet
Rating Summary:
10 Buy, 18 Hold, 5 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 15 | Down: 11 | New: 13
Join SI Premium – FREE
Cowen reiterated a Market Perform rating on Seattle Genetics (NASDAQ: SGEN), and raises the price target to $40.50 (from $34.00), following 2Q15 results. SGEN posted Adcetris sales of $55.1M for 2Q15, ahead of consensus $50.9M estimates.
Analyst Boris Peaker commented, "SGEN reported 2Q15 results. Adcetris had a strong quarter ($55M; +23% Y/Y) and has already seen some post-transplant use ahead of the August 18th PDUFA. Management discussed development plans for SGN-CD33A and suggested the potential for accelerated approval and plans to have an end of Phase I meeting with the FDA by YE. We maintain at Market Perform."
For an analyst ratings summary and ratings history on Seattle Genetics click here. For more ratings news on Seattle Genetics click here.
Shares of Seattle Genetics closed at $47.34 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Quest Diagnostics (DGX) PT Raised to $145 at Evercore ISI
- CLSA Downgrades Denso Corp. (6902:JP) (DNZOY) to Sell (5)
- Angel Yeast Co Ltd (600298:CH) PT Lowered to RMB35 at Macquarie
Create E-mail Alert Related Categories
Analyst Comments, Analyst EPS Change, Analyst EPS View, Analyst PT ChangeRelated Entities
Cowen & CoSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!